Structural Basis for Inhibition of Protein-tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics*
- Paul J. Ala1,
- Lucie Gonneville,
- Milton C. Hillman,
- Mary Becker-Pasha,
- Min Wei,
- Brian G. Reid,
- Ronald Klabe,
- Eddy W. Yue,
- Brian Wayland,
- Brent Douty,
- Padmaja Polam,
- Zelda Wasserman,
- Michael Bower,
- Andrew P. Combs,
- Timothy C. Burn,
- Gregory F. Hollis and
- Richard Wynn
- ↵1 To whom correspondence should be addressed: Incyte Corp., Experimental Station, Rte. 141 and Henry Clay Rd., Wilmington, DE 19880. E-mail: pauljala{at}gmail.com.
Abstract
Crystal structures of protein-tyrosine phosphatase 1B in complex with compounds bearing a novel isothiazolidinone (IZD) heterocyclic phosphonate mimetic reveal that the heterocycle is highly complementary to the catalytic pocket of the protein. The heterocycle participates in an extensive network of hydrogen bonds with the backbone of the phosphate-binding loop, Phe182 of the flap, and the side chain of Arg221. When substituted with a phenol, the small inhibitor induces the closed conformation of the protein and displaces all waters in the catalytic pocket. Saturated IZD-containing peptides are more potent inhibitors than unsaturated analogs because the IZD heterocycle and phenyl ring directly attached to it bind in a nearly orthogonal orientation with respect to each other, a conformation that is close to the energy minimum of the saturated IZD-phenyl moiety. These results explain why the heterocycle is a potent phosphonate mimetic and an ideal starting point for designing small nonpeptidic inhibitors.
- Received July 19, 2006.
- Revision received August 14, 2006.
- The American Society for Biochemistry and Molecular Biology, Inc.











